Sign In
Buy NDAQ
$77.65
-3.96 (-4.85%)
At Close: Jun 25, 2026
Altamira Therapeutics Provides Update on Nasdaq Listing
04:01pm, Friday, 04'th Oct 2024
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter fro
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Oct 2024
BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 202
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 04'th Oct 2024
WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Nasdaq Gains Over 100 Points; Beneficient Shares Spike Higher
02:32pm, Friday, 04'th Oct 2024
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.
China's BingEx opens flat in Nasdaq debut
11:03am, Friday, 04'th Oct 2024
China's BingEx notched a valuation of $1.17 billion in its Nasdaq debut on Friday, after shares of the courier delivery firm traded in line with its initial public offering price.
Vision Marine Technologies Granted Extension for Continued Listing on the Nasdaq Stock Market
09:30am, Friday, 04'th Oct 2024
Vision Marine Announces Reverse Stock Split to Regain Nasdaq Compliance MONTREAL, QC / ACCESSWIRE / October 4, 2024 / Vision Marine Technologies Inc. (the "Company") (NASDAQ:VMAR), a pioneer in electr
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:01am, Friday, 04'th Oct 2024
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 03'rd Oct 2024
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Nasdaq Moves Lower; Levi Strauss Shares Slide
02:53pm, Thursday, 03'rd Oct 2024
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 03'rd Oct 2024
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 2
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
07:12pm, Wednesday, 02'nd Oct 2024
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
06:35pm, Wednesday, 02'nd Oct 2024
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories Company Obtains Participation from New and Existing Investors, Including Strategic Partn
Innventure LLC and Learn CW Investment Corporation Announce Closing of Business Combination
04:45pm, Wednesday, 02'nd Oct 2024
Innventure Common Stock Expected to Begin Trading on October 3, 2024, on the Nasdaq Global Market Under Ticker Symbol “INV” Innventure Common Stock Expected to Begin Trading on October 3, 2024, on
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 02'nd Oct 2024
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, d
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 02'nd Oct 2024
WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies
